Vildagliptin
Inflammatory Disease
Rio de Janeiro State UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Inflammatory Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Methoxy Polyethylene Glycol-Epoetin Beta Taipei Veterans General Hospital, Taiwan | Phase 4 | BB |
Itavastatin Aichi Gakuin University | Phase 4 | BB |
Sitagliptin University of Southern California | Phase 3 | BB |
Sufentanyl The First Affiliated Hospital with Nanjing Medical University | Phase 4 | BB |
Pioglitazone National Institute on Aging (NIA) | Phase 4 | B |
View all 50 →
Same molecule, other indications
Vildagliptin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →